# The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

> **NCT05931328** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 28 (estimated)

## Conditions studied

- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** thiotepa combined with pomalidomide

## Key facts

- **NCT ID:** NCT05931328
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-15
- **Primary completion:** 2024-10
- **Final completion:** 2026-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931328, "The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05931328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*